Viruses and tumours - An update

European Journal of Cancer

Volumn 40, Issue 13, 2004, Pages 1998-2005

  Talbot, Simon J ^a   Crawford, Dorothy H ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Cancer; Casuality; Herpesviruses; Molecular biology; Viruses

Indexed keywords

TUMOR ANTIGEN; TUMOR SUPPRESSOR PROTEIN;

ADENOVIRUS; BURKITT LYMPHOMA; CELL TRANSFORMATION; CHILDHOOD LEUKEMIA; DISEASE ASSOCIATION; DNA VIRUS; FLAVIVIRUS; GENE THERAPY; GENE VECTOR; HEMATOLOGIC MALIGNANCY; HEPADNAVIRIDAE; HEPATITIS C VIRUS; HERPES VIRUS; HISTORY; HUMAN; HUMAN HERPESVIRUS 8; HUMAN T CELL LEUKEMIA VIRUS 1; MALIGNANT NEOPLASTIC DISEASE; MEDICAL LITERATURE; MOLECULAR BIOLOGY; MOLECULAR GENETICS; NONHUMAN; ONCOGENE; PAPOVAVIRUS; PRIORITY JOURNAL; RETROVIRUS; REVIEW; T CELL LEUKEMIA; VIRUS CARCINOGENESIS; VIRUS IDENTIFICATION;

EID: 4143140859     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2003.11.039     Document Type: Article

References (61)

1. Harris R.J. Viruses and tumours. Eur. J. Cancer. 1:1965;183-188
2. Parkin D.M., Bray F., Ferlay J., Pisani P. Estimating the world cancer burden: Globocan 2000. Int. J. Cancer. 94:2001;153-156
3. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189:1999;12-19
4. IARC. Human Papillomaviruses (IARC Monographs on the Evaluation of Carcinogenic Risks to Humans) 64, 1995, Lyon
5. IARC. Hepatitis Viruses (IARC Monographs on the Evaluation of Carcinogenic Risks to Humans) 59, 1994, Lyon
6. IARC. Human Immunodeficiency Viruses and Human T-cell Lymphotropic Viruses (IARC Monographs on the Evaluation of Carcinogenic Risks to Humans) 67, 1996, Lyon
7. IARC. Epstein-Barr Virus and Kaposi's Sarcoma Herpesvirus/Human Herpesvirus 8 (IARC Monographs on the Evaluation of Carcinogenic Risks to Humans) 70, 1997, Lyon
8. Kinlen L.J. Infection and childhood leukemia. Cancer Causes Control. 9:1998;237-239
9. Tjian R., Robbins A. Enzymatic activities associated with a purified simian virus40 T antigen-related protein. Proc. Natl. Acad. Sci. USA. 76:1979;610-614
10. Ballestas M.E., Chatis P.A., Kaye K.M. Efficient persistence of extrachromosomal KSHV DNA mediated by latency-associated nuclear antigen. Science. 284:1999;641-644
11. Friborg J. Jr., Kong W., Hottiger M.O., Nabel G.J. p53 inhibition by the LANA protein of KSHV protects against cell death. Nature. 402:1999;889-894
12. Radkov S.A., Kellam P., Boshoff C. The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells. Nat. Med. 6:2000;1121-1127
13. Fujimuro M., Wu F.Y., ApRhys C., Kajumbula H., Young D.B., Hayward G.S., et al. A novel viral mechanism for dysregulation of beta-catenin in Kaposi's sarcoma-associated herpesvirus latency. Nat. Med. 9:2003;300-306
14. Temin H.M. Genetic and possible biochemical mechanisms in viral carcinogenesis. Cancer Res. 26:1966;212-216
15. Baltimore D. RNA-dependent DNA polymerase in virions of RNA tumour viruses. Nature. 226:1970;1209-1211
16. Temin H.M., Mizutani S. RNA-dependent DNA polymerase in virions of Rous sarcoma virus. Nature. 226:1970;1211-1213
17. Kinlen L.J., Balkwill A. Infective cause of childhood leukaemia and wartime population mixing in Orkney and Shetland, UK. Lancet. 357:2001;858
18. Kinlen L.J., Dickson M., Stiller C.A. Childhood leukaemia and non-Hodgkin's lymphoma near large rural construction sites, with a comparison with Sellafield nuclear site. BMJ. 310:1995;763-768
19. Poiesz B.J., Ruscetti F.W., Gazdar A.F., Bunn P.A., Minna J.D., Gallo R.C. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc. Natl. Acad. Sci. USA. 77:1980;7415-7419
20. Mortreux F., Gabet A.S., Wattel E. Molecular and cellular aspects of HTLV-1 associated leukemogenesis in vivo. Leukemia. 17:2003;26-38
21. Yoshida M. Multiple viral strategies of HTLV-1 for dysregulation of cell growth control. Annu. Rev. Immunol. 19:2001;475-496
22. Vijaya S., Steffen D.L., Robinson H.L. Acceptor sites for retroviral integrations map near DNase I-hypersensitive sites in chromatin. J. Virol. 60:1986;683-692
23. Cavazzana-Calvo M., Hacein-Bey S., de Saint B.G., Gross F., Yvon E., Nusbaum P., et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 288:2000;669-672
24. Kohn D.B., Sadelain M., Glorioso J.C. Occurrence of leukaemia following gene therapy of X-linked SCID. Nat. Rev. Cancer. 3:2003;477-488
25. Royer-Pokora B., Loos U., Ludwig W.D. TTG-2, a new gene encoding a cysteine-rich protein with the LIM motif, is overexpressed in acute T-cell leukaemia with the t(11;14)p(13;q11). Oncogene. 6:1991;1887-1893
26. Li Z., Dullmann J., Schiedlmeier B., Schmidt M., von Kalle C., Meyer J., et al. Murine leukemia induced by retroviral gene marking. Science. 296:2002;497
27. Burkitt D. A sarcoma involving the jaws of African children. Brit. J. Surg. 46:1958;218-223
28. Burkitt D. Determining the climatic limitations of a childrens cancer common in Africa. Brit. Med. J. 2:1962;1019-1023
29. Epstein M.A., Barr Y.M., Achong B.G. Virus particles in cultured lymphoblasts from Burkitts lymphoma. Lancet. 1:1964;702-803
30. de The G., Geser A., Day N.E., Tukei P.M., Williams E.H., Beri D.P., et al. Epidemiological evidence for causal relationship between Epstein-Barr virus and Burkitt's lymphoma from Ugandan prospective study. Nature. 274:1978;756-761
31. Deinhardt F., Deinhardt J. Comparative aspects: oncogenic animal herpesviruses. Epstein M.A., Achong B.G. The Epstein-Barr virus. 1979;373-415 Springer-Verlag, Berlin, Heidelberg, New York
32. Pope J.H., Horne M.K., Scott W. Transformation of foetal human keukocytes in vitro by filtrates of a human leukaemic cell line containing herpes-like virus. Int. J. Cancer. 3:1968;857-866
33. Baer R., Bankier A.T., Biggin M.D., Deininger P.L., Farrell P.J., Gibson T.J., et al. DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature. 310:1984;207-211
34. Bornkamm G.W., Hammerschmidt W. Molecular virology of Epstein-Barr virus. Philos. Trans. R. Soc. Lond B: Biol. Sci. 356:2001;437-459
35. Young L.S., Dawson C.W., Eliopoulos A.G. The expression and function of Epstein-Barr virus encoded latent genes. Mol. Pathol. 53:2000;238-247
36. Gregory C.D., Edwards C.F., Milner A., Wiels J., Lipinski M., Rowe M., et al. Isolation of a normal B cell subset with a Burkitt-like phenotype and transformation in vitro with Epstein-Barr virus. Int. J. Cancer. 42:1988;213-220
37. Raab-Traub N., Flynn K. The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation. Cell. 47:1986;883-889
38. Yates J.L., Warren N., Sugden B. Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature. 313:1985;812-815
39. Rowe M., Rowe D.T., Gregory C.D., Young L.S., Farrell P.J., Rupani H., et al. Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J. 6:1987;2743-2751
40. Komano J., Maruo S., Kurozumi K., Oda T., Takada K. Oncogenic role of Epstein-Barr virus-encoded RNAs in Burkitt's lymphoma cell line Akata. J. Virol. 73:1999;9827-9831
41. Kelly G., Bell A., Rickinson A. Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2. Nat. Med. 8:2002;1098-1104
42. Zech L., Haglund U., Nilsson K., Klein G. Characteristic chromosomal abnormalities in biopsies and lymphoid-cell lines from patients with Burkitt and non-Burkitt lymphomas. Int. J. Cancer. 17:1976;47-56
43. Farrell P.J., Allan G.J., Shanahan F., Vousden K.H., Crook T. p53 is frequently mutated in Burkitt's lymphoma cell lines. EMBO J. 10:1991;2879-2887
44. Kohler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 256:1975;495-497
45. Penn I. The changing pattern of posttransplant malignancies. Transplant. Proc. 23:1991;1101-1103
46. Haque T., Crawford D.H. The role of adoptive immunotherapy in the prevention and treatment of lymphoproliferative disease following transplantation. Br. J. Haematol. 106:1999;309-316
47. Hopwood P., Crawford D.H. The role of EBV in post-transplant malignancies: a review. J. Clin. Pathol. 53:2000;248-254
48. Heslop H.E., Ng C.Y., Li C., Smith C.A., Loftin S.K., Krance R.A., et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat. Med. 2:1996;551-555
49. Rooney C.M., Smith C.A., Ng C.Y., Loftin S., Li C., Krance R.A., et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet. 345:1995;9-13
50. Haque T., Wilkie G.M., Taylor C., Amlot P.L., Murad P., Iley A., et al. Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet. 360:2002;436-442
51. Kaposi M. Arch. Dermatol. Syphillis. 4:1872;265-273
52. Beral V., Newton R. Overview of the epidemiology of immunodeficiency- associated cancers. J. Natl. Cancer Inst. Monogr. 1998;1-6
53. Chang Y., Cesarman E., Pessin M.S., Lee F., Culpepper J., Knowles D.M., et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science. 266:1994;1865-1869
54. Lisitsyn N., Lisitsyn N., Wigler M. Cloning the differences between two complex genomes. Science. 259:1993;946-951
55. Choo Q.L., Kuo G., Weiner A.J., Overby L.R., Bradley D.W., Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 244:1989;359-362
56. Farci P., Shimoda A., Coiana A., Diaz G., Peddis G., Melpolder J.C., et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science. 288:2000;339-344
57. Otsuka M., Kato N., Lan K., Yoshida H., Kato J., Goto T., et al. Hepatitis C virus core protein enhances p53 function through augmentation of DNA binding affinity and transcriptional ability. J. Biol. Chem. 275:2000;34122-34130
58. Kinlen L.J., Sheil A.G., Peto J., Doll R. Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs. Br. Med. J. 2:1979;1461-1466
59. Birkeland S.A., Storm H.H., Lamm L.U., Barlow L., Blohme I., Forsberg B., et al. Cancer risk after renal transplantation in the Nordic countries, 1964-1986. Int. J. Cancer. 60:1995;183-189
60. Ford C.E., Tran D., Deng Y., Ta V.T., Rawlinson W.D., Lawson J.S. Mouse mammary tumor virus-like gene sequences in breast tumors of Australian and Vietnamese women. Clin. Cancer Res. 9:2003;1118-1120
61. Witt A., Hartmann B., Marton E., Zeillinger R., Schreiber M., Kubista E. The mouse mammary tumor virus-like env gene sequence is not detectable in breast cancer tissue of Austrian patients. Oncol. Rep. 10:2003;1025-1029